MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Effectiveness of a novel cognitive rehabilitation program based on mindfulness and reminiscence in patients with Parkinson’s Disease and Mild Cognitive Impairment: a pilot study

M. Reitano, M. Dini, F. Ruggiero, S. Tagini, F. Solca, B. Poletti, A. Priori, R. Ferrucci (Milan, Italy)
Effectiveness of an intensive and structured therapy (LSVT-BIG) in comparison to conventional therapy for people with Parkinson’s disease in Singapore.

D. Maniam, JQ. Yong, V. Tan (Singapore, Singapore)
EFFECTIVENESS OF NEUROFUNCTIONAL PHYSICAL THERAPY ON THE QUALITY OF SLEEP OF INDIVIDUALS WITH PARKINSON’S DISEASE: A SERIES OF CASES

R. Souza, S. Smaili, I. Almeida, M. Terra, N. Barboza, ME. Bueno, A. Mesas (Londrina, Brazil)
Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study

W. Jost, H. Reichmann, A. Lees, D. Marinho, D. Magalhães, J. Rocha, P. Soares-da-Silva (Wolfach, Germany)
Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study

H. Reichmann, T. Warnecke, A. Lees, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)
Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

N. Pavese, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Newcastle Upon Tyne, United Kingdom)
Effectiveness of the use of home-based action observation training in subjects with Parkinson’s disease

M. Putzolu, C. Cosentino, S. Mezzarobba, G. Bonassi, A. Botta, G. Lagravinese, C. Ponte, L. Avanzino, E. Pelosin (Genoa, Italy)
Effects of Angiotensin Type 1 Receptor Antagonists on Parkinson’s Disease Progression: an exploratory study in the PPMI database

L. Udovin, M. Otero-Losada, S. Bordet, G. Chevalier, C. Quarracino, F. Capani, S. Perez-Lloret (Buenos Aires, Argentina)
Effects of dopaminergic medication on reinforcement learning in Parkinson’s disease depend on depressive symptoms

J. Tichelaar, C. Sayali, R. Helmich, R. Cools (Nijmegen, Netherlands)
Effects of fine particulate matter and cigarette smoking on MPTP-induced dopaminergic neuronal cell death: Implication for Parkinson’s disease

YJ. Jung, H. Choi, E. Oh (Seoul, Republic of Korea)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z